TW201639878A - 具有改善之安定性的升糖素衍生物 - Google Patents

具有改善之安定性的升糖素衍生物 Download PDF

Info

Publication number
TW201639878A
TW201639878A TW104144427A TW104144427A TW201639878A TW 201639878 A TW201639878 A TW 201639878A TW 104144427 A TW104144427 A TW 104144427A TW 104144427 A TW104144427 A TW 104144427A TW 201639878 A TW201639878 A TW 201639878A
Authority
TW
Taiwan
Prior art keywords
acid
cysteine
receptor
glycoside
glutamic acid
Prior art date
Application number
TW104144427A
Other languages
English (en)
Chinese (zh)
Inventor
金正國
李鍾旻
金尚允
裵城敏
鄭聖燁
權世昌
Original Assignee
韓美藥品股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 韓美藥品股份有限公司 filed Critical 韓美藥品股份有限公司
Publication of TW201639878A publication Critical patent/TW201639878A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW104144427A 2014-12-30 2015-12-30 具有改善之安定性的升糖素衍生物 TW201639878A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20140193800 2014-12-30

Publications (1)

Publication Number Publication Date
TW201639878A true TW201639878A (zh) 2016-11-16

Family

ID=56284642

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104144427A TW201639878A (zh) 2014-12-30 2015-12-30 具有改善之安定性的升糖素衍生物

Country Status (28)

Country Link
US (1) US11135271B2 (OSRAM)
EP (2) EP3241841A4 (OSRAM)
JP (2) JP6797122B2 (OSRAM)
KR (1) KR102291020B1 (OSRAM)
CN (1) CN107636009B (OSRAM)
AR (1) AR103322A1 (OSRAM)
AU (1) AU2015372818A1 (OSRAM)
CL (1) CL2017001718A1 (OSRAM)
CO (1) CO2017006308A2 (OSRAM)
CR (1) CR20170293A (OSRAM)
DO (1) DOP2017000156A (OSRAM)
EA (1) EA035527B1 (OSRAM)
EC (1) ECSP17040923A (OSRAM)
ES (1) ES2976562T3 (OSRAM)
GT (1) GT201700150A (OSRAM)
HK (1) HK1248713A1 (OSRAM)
IL (2) IL253206B (OSRAM)
MA (1) MA40709B1 (OSRAM)
MX (1) MX2017008569A (OSRAM)
MY (1) MY185334A (OSRAM)
PE (2) PE20171154A1 (OSRAM)
PH (1) PH12017501222B1 (OSRAM)
SG (1) SG11201705376SA (OSRAM)
TN (1) TN2017000271A1 (OSRAM)
TW (1) TW201639878A (OSRAM)
UA (1) UA126960C2 (OSRAM)
WO (1) WO2016108586A1 (OSRAM)
ZA (1) ZA201705015B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
AU2016287209B2 (en) * 2015-06-30 2023-03-02 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
PT3398961T (pt) 2015-12-31 2022-09-05 Hanmi Pharm Ind Co Ltd Ativador triplo ativando recetor glucagon, glp-1 e gip
JP7208020B2 (ja) * 2016-06-29 2023-01-18 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途
EP3578204A4 (en) 2017-02-03 2021-01-06 Hanmi Pharm. Co., Ltd. BIOACTIVE SUBSTANCE CONJUGATE WITH ENHANCED DURABILITY AND ITS USE
US12435328B2 (en) * 2017-12-22 2025-10-07 Hanmi Pharm. Co., Ltd. Therapeutic enzyme fusion protein having a novel structure and use thereof
CN111936159A (zh) * 2018-01-23 2020-11-13 Xeris药物公司 使用微剂量的稳定胰高血糖素治疗减肥术后低血糖症
WO2020130751A1 (ko) 2018-12-21 2020-06-25 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
KR20210144606A (ko) 2020-05-22 2021-11-30 한미약품 주식회사 글루카곤 유도체의 지속형 결합체의 액상 제제
EP4183407A4 (en) 2020-07-15 2024-08-14 Hanmi Pharm. Co., Ltd. THERAPEUTIC USE OF A GLUCAGNONE DERIVATIVE OR CONJUGATE THEREOF FOR LIVER DISEASES
CN117157094A (zh) 2021-04-09 2023-12-01 韩美药品株式会社 包括胰高血糖素衍生物的用于预防或治疗慢性肾病的药物组合物
KR20230095666A (ko) 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도
CN115490760B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
EA009366B1 (ru) 2003-03-19 2007-12-28 Эли Лилли Энд Компани Связанные с полиэтиленгликолем соединения гпп-1
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
ES2438098T3 (es) 2003-11-13 2014-01-15 Hanmi Science Co., Ltd. Composición farmacéutica que comprende un Fc de inmunoglobulina como vehículo
CA2800389A1 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
EP2124974B1 (en) * 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
BRPI0807728A2 (pt) 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp co-agonistas de receptor glucagon/glp-1
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
CA2696615A1 (en) 2007-06-19 2008-12-24 Otsuka Chemical Co., Ltd. Oligosaccharide chain added glp-1 peptide
JP5476304B2 (ja) * 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
KR20110039230A (ko) 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
SG192405A1 (en) 2008-06-17 2013-08-30 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
RU2012101274A (ru) 2009-06-16 2013-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соединения глюкагона, активные в отношении рецептора gip
KR101809024B1 (ko) 2009-07-13 2017-12-14 질랜드 파마 에이/에스 아실화 글루카곤 유사체
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP2013517307A (ja) 2010-01-20 2013-05-16 ジーランド ファーマ アクティーゼルスカブ 心臓病の処置
EP2552950A1 (en) * 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
KR20240110072A (ko) 2011-05-18 2024-07-12 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
SG10201604564XA (en) 2011-06-10 2016-07-28 Hanmi Science Co Ltd Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
HRP20190265T1 (hr) * 2011-06-17 2019-04-05 Hanmi Science Co., Ltd. Konjugat koji sadrži oksintomodulin i fragment imunoglobulina i njegova uporaba
JP6396211B2 (ja) 2011-07-04 2018-09-26 インペリアル・イノベイションズ・リミテッド 新規化合物及び摂食行動に対するそれらの効果
WO2013074910A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
RS57347B1 (sr) 2012-06-21 2018-08-31 Univ Indiana Res & Tech Corp Analozi glukagona koji ispoljavaju aktivnost gip receptora
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
TWI816739B (zh) 2012-11-06 2023-10-01 南韓商韓美藥品股份有限公司 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
US11065304B2 (en) 2012-11-20 2021-07-20 Mederis Diabetes, Llc Peptide pharmaceuticals for insulin resistance
DK2922877T3 (da) 2012-11-20 2019-01-02 Eumederis Pharmaceuticals Inc Forbedrede peptidlægemidler
HRP20181300T1 (hr) 2012-12-21 2018-10-05 Sanofi Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
HK1226084A1 (zh) 2013-08-16 2017-09-22 Medimmune Limited 用於治疗糖尿病的gip和glp-1受体双重激动剂
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
AU2016287209B2 (en) * 2015-06-30 2023-03-02 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
PT3398961T (pt) 2015-12-31 2022-09-05 Hanmi Pharm Ind Co Ltd Ativador triplo ativando recetor glucagon, glp-1 e gip

Also Published As

Publication number Publication date
IL281375B (en) 2021-10-31
JP2020188819A (ja) 2020-11-26
EP3575314A3 (en) 2020-01-22
PH12017501222A1 (en) 2018-01-15
AU2015372818A1 (en) 2017-07-27
ZA201705015B (en) 2018-04-25
IL253206B (en) 2021-10-31
IL253206A0 (en) 2017-08-31
PE20171154A1 (es) 2017-08-16
JP2018504901A (ja) 2018-02-22
MY185334A (en) 2021-05-06
EP3575314B1 (en) 2024-02-14
MA40709A1 (fr) 2017-12-29
DOP2017000156A (es) 2017-10-15
CN107636009B (zh) 2021-04-16
PE20230304A1 (es) 2023-02-13
SG11201705376SA (en) 2017-08-30
NZ733464A (en) 2024-01-26
CA2972748A1 (en) 2016-07-07
MA40709B1 (fr) 2019-07-31
EP3575314A2 (en) 2019-12-04
TN2017000271A1 (en) 2018-10-19
CN107636009A (zh) 2018-01-26
CR20170293A (es) 2017-11-03
ECSP17040923A (es) 2017-12-01
JP6797122B2 (ja) 2020-12-09
EA035527B1 (ru) 2020-06-30
NZ770767A (en) 2024-04-26
EP3241841A1 (en) 2017-11-08
WO2016108586A1 (ko) 2016-07-07
GT201700150A (es) 2018-12-12
PH12017501222B1 (en) 2024-07-03
CL2017001718A1 (es) 2018-01-12
EP3241841A4 (en) 2018-10-17
IL281375A (en) 2021-04-29
UA126960C2 (uk) 2023-03-01
BR112017014205A2 (pt) 2018-03-06
CO2017006308A2 (es) 2017-09-29
JP7079301B2 (ja) 2022-06-01
ES2976562T3 (es) 2024-08-05
US11135271B2 (en) 2021-10-05
AR103322A1 (es) 2017-05-03
MX2017008569A (es) 2017-10-20
US20170360892A1 (en) 2017-12-21
EP3575314C0 (en) 2024-02-14
EA201791333A1 (ru) 2017-12-29
HK1248713A1 (en) 2018-10-19
KR102291020B1 (ko) 2021-08-20
KR20160082482A (ko) 2016-07-08

Similar Documents

Publication Publication Date Title
JP7079301B2 (ja) 安定性が増加されたグルカゴン誘導体
TWI619724B (zh) 新穎之調酸素衍生物及含有該衍生物之用於治療肥胖之醫藥組成物
US11254724B2 (en) Glucagon derivatives
CA2972748C (en) Glucagon derivatives with improved stability
HK40010066A (en) Glucagon derivative
HK40010066B (en) Glucagon derivative
BR112017014205B1 (pt) Derivados de glucagon e seu uso, e uso de uma composição farmacêutica
HK1246323B (en) Glucagon derivatives
NZ740049B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ717174B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ755534B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ734808B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same